Evidence map›Paper›PMID 41690369›Full record

ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2026

Airway molecular signatures in antibody-mediated lung transplant rejection.

Rashmi Prava Mohanty, Daniel R Calabrese, Kaveh Moghbeli, Carlo J Iasella, Kaitlyn Devonshire, Amanda Zeng, Kong Chen, Jonathan P Singer, Steven R Hays, Lorriana E Leard and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Rashmi Prava MohantyDivision of Pulmonary, Critical Care, Allergy and Sleep, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
Daniel R CalabreseDivision of Pulmonary, Critical Care, Allergy and Sleep, Department of Medicine, University of California San Francisco, San Francisco, California, USA; Medical Service, San Francisco VA Health Care System, California, USA.
Kaveh MoghbeliDivision of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Carlo J IasellaDepartment of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania, USA.
Kaitlyn DevonshireDivision of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Amanda ZengDivision of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Kong ChenDivision of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Jonathan P SingerDivision of Pulmonary, Critical Care, Allergy and Sleep, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
Steven R HaysDivision of Pulmonary, Critical Care, Allergy and Sleep, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
Lorriana E LeardDivision of Pulmonary, Critical Care, Allergy and Sleep, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
Aida Venado EstradaDivision of Pulmonary, Critical Care, Allergy and Sleep, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
Rupal J ShahDivision of Pulmonary, Critical Care, Allergy and Sleep, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
Nicholas A KolaitisDivision of Pulmonary, Critical Care, Allergy and Sleep, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
Jeffrey A GoldenDivision of Pulmonary, Critical Care, Allergy and Sleep, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
Charles R LangelierChan Zuckerberg Biohub, San Francisco, California, USA; Division of Infectious Diseases, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
John F McDyerDivision of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
John R GreenlandDivision of Pulmonary, Critical Care, Allergy and Sleep, Department of Medicine, University of California San Francisco, San Francisco, California, USA; Medical Service, San Francisco VA Health Care System, California, USA. Electronic address: john.greenland@ucsf.edu.

Funding

Long Term Follow up of the Lung Transplant Outcomes Group CohortU01HL145435 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI CHRISTIE, JASON D, PALMER, SCOTT M · 2019 to 2025
$10.2M
Frailty and patient centered outcomes in candidates for lung transplantationR01HL134851 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SINGER, JONATHAN PAUL · 2017 to 2021
$3.4M
Airway epithelial cell and lymphocyte interactions in chronic lung allograft dysfunction pathogenesisR01HL161048 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHN GREENLAND, TEREZA MARTINU · 2022 to 2026
$3.3M
CSRD VA I01 CX002011NHLBI NIH HHS R01 HL134851NHLBI NIH HHS R01 HL161048NHLBI NIH HHS U01 HL145435
6 · The paper itself

Abstract

Severe antibody-mediated rejection (AMR) is associated with chronic lung allograft dysfunction (CLAD) and death in lung transplant recipients. However, AMR diagnostics are imprecise, and new biomarkers are needed. We assessed whether airway inflammation gene signatures could distinguish AMR cases from controls. We analyzed small airway brush RNA sequencing from 16 AMR cases and 39 controls across 2 centers. We compared gene signatures for complement activation, molecular target of rapamycin (mTOR) signaling, and natural killer cell-mediated injury. Differential gene expression and pathway analyses sought AMR molecular features. Additionally, we evaluated the airway inflammation 2 (AI2) score, previously associated with CLAD and graft failure, in relation to AMR clinical features and survival outcomes. AMR airway brushes demonstrated transcriptional evidence of airway inflammation and upregulation of complement and natural killer cell pathways. The AI2 score was significantly elevated in AMR cases (P < .001) and was associated with AMR-compatible histology, donor-specific antibodies, complement binding, and acute graft dysfunction. Increasing AI2 scores were associated with worse retransplant-free survival, independent of other AMR features. In small airways, lung transplant AMR predominantly exhibits molecular features of cellular rejection rather than a distinct humoral rejection profile. Airway brush transcriptomics may provide a valuable tool for characterizing and prognosticating suspected AMR.

Indexed as

BiomarkersGraft RejectionIsoantibodiesLung TransplantationAdultCase-Control StudiesFemaleFollow-Up StudiesGraft SurvivalHumansMaleMiddle AgedPrognosisRisk FactorsBiomarkersIsoantibodiesantibody-mediated rejectionchronic lung allograft dysfunctionlung transplantationmolecular diagnosticssmall airways

Identifiers

PMID41690369
PMCPMC13271768

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.